Clever Culture Systems Expanded Biotech Platform Adoption
The firm increased its automated microbiology instrument base to 37 units globally.
Updated on Oct. 1, 2026 in Biotech
Live Poll
Do you trust pharmaceutical companies more when they use AI to automate laboratory safety testing?
Clever Culture Systems has scaled the deployment of its APAS Independence platform within pharmaceutical manufacturing networks. The technology automates microbiology culture plate reading, improving efficiency and data integrity.
Why it matters
Automated microbiology platforms represent a significant shift toward digital laboratory processes that reduce manual error. By securing major pharmaceutical clients, Clever Culture Systems is establishing a standardized approach to culture analysis at scale.
The APAS Independence platform utilizes AI-powered processing to replace manual microbiology plate reading. The company currently supports an installed base of 37 instruments across eight major pharmaceutical customers.
The players
Clever Culture Systems
A biotech firm that trades under the ASX ticker CC5 and focuses on automated laboratory solutions.
AstraZeneca
A multinational pharmaceutical company that has purchased 12 of the APAS Independence instruments.
Novo Nordisk
A global healthcare company that currently operates three APAS Independence instruments.
The details
The platform functions by automating the reading and reporting of microbiology culture plates, a process traditionally handled by manual labor. Clever Culture Systems typically begins by placing initial systems with a client before rolling out deployment across their wider manufacturing network.
Timeline
FY27: Projected step-up in commercial activity for the company.
The Big Picture
The deployment of the APAS Independence platform marks a broader industry trend toward digitizing laboratory quality control. This move follows a documented shift in biotechnology to replace labor-intensive manual inspection with standardized AI analysis.
The adoption of these systems standardizes quality control processes for major pharmaceutical manufacturers. Users within these labs benefit from improved efficiency and consistent data integrity compared to manual plate processing methods.
The takeaway
Clever Culture Systems expects more than 50% of its sales in FY27 to originate from existing customers who are scaling their infrastructure. This strategy indicates a shift toward long-term reliance on automated diagnostic platforms within the pharmaceutical sector.
Further reading
Learn more about the latest innovations in Biotech.
Live Poll
Do you trust pharmaceutical companies more when they use AI to automate laboratory safety testing?
